Tandem Diabetes Care outlines path to $1B sales milestone and gross margin gains in 2025 while expanding pharmacy channel

Earnings Call Insights: Tandem Diabetes Care (TNDM) Q3 2025

MANAGEMENT VIEW

* John Sheridan, President and CEO, highlighted "significant strategic milestones and delivered record Q3 sales" and stated, "Our substantial progress is starting to become evident in our financial results and serves as a testament to our strategic vision, hard work and the collective dedication of our entire team." He identified three primary initiatives: modernization of commercial operations, driving innovation, and reshaping the business model.
* Sheridan emphasized the U.S. commercial transformation, noting improved sales productivity from new technology platforms and organizational restructuring. He reported, "Pump shipments for Q3 met our expectations with favorable underlying sales trends and September was our strongest month of the quarter."
* The CEO pointed to expanding direct international operations in Europe, starting in the U.K., Switzerland, and Austria in early 2026, and said, "Establishing direct international operations is a critical step to strengthen our financial position by accelerating sales growth and driving margin expansion."
* Sheridan shared progress in product integration, stating, "Last week, we announced that t:slim X2 is now fully available with Abbott's FreeStyle Libre 3 Plus integration in the U.S., marking the first step in a broader global rollout."
* Addressing the Type 2 diabetes market, Sheridan explained that positive feedback has led to expansion from pilot to full promotion of Control-IQ+ for Type 2, noting, "Serving this population is a focus for us because it offers meaningful longer-term growth opportunity, doubling our addressable market in the U.S."
* The CEO described the advancement of a multichannel reimbursement strategy, including pharmacy channel expansion, stating, "We've successfully increased pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives... Early uptake has been encouraging with customers citing affordability, convenience and simplified refills as the top reasons for switching."
* Leigh Vosseller, CFO, stated, "With revenue of $249 million, we once again set record third quarter sales. Our top line outperformance was primarily driven by ASP increases on both pumps and supplies in the U.S. as well as favorable foreign currency dynamics."
* Vosseller added, "Our Q3 gross margin of 54% increased approximately 3 percentage points year-over-year and increased approximately 2 percentage points compared to Q2. Like sales, this reflects meaningful benefit from higher ASPs."

OUTLOOK

* Vosseller reaffirmed full-year 2025 expectations, stating, "We are on track to achieve double-digit growth at a milestone of $1 billion in worldwide sales. This includes U.S. sales of approximately $700 million... Outside the U.S., we anticipate sales of approximately $300 million."
* She also reaffirmed gross margin expectations: "We are reaffirming our 2025 gross margin expectation in the range of 53% to 54% of sales, with Q4 expected to be an all-time gross margin record in the mid- to high 50s."
* Vosseller provided context for 2026, anticipating "returning to new pump growth driven by MDI conversions from new product introductions and increased pharmacy access" and targeting gross margin of at least 60% in Q4 2026.

FINANCIAL RESULTS

* Revenue for Q3 was $249 million.
* U.S. sales were approximately $176 million and international sales reached $74 million.
* Gross margin reached 54% for Q3.
* Operating expenses increased 4% year-over-year, attributed to SG&A investments, with $3 million in restructuring costs included.
* The company ended the quarter with $319 million in total cash and investments.

Q&A

* Matthew Miksic, Barclays: Asked about acceleration catalysts for 2026. Sheridan said Mobi, the Android approval, the international roll-out, and the tubeless version will drive growth, stating, "We feel very confident we're going to make these things happen in 2026."
* Larry Biegelsen, Wells Fargo: Inquired about price uplift from supplies via pharmacy. Vosseller responded that Q3 saw a shift where pharmacy operations became the primary driver of price increases, and current trends can serve as a baseline for 2026.
* Christopher Pasquale, Nephron Research: Asked about Q4 seasonality. Vosseller indicated expectations are based on last year’s 30% of full-year shipments occurring in Q4, with renewal opportunities underpinning the quarter’s step-up.
* Danielle Antalffy, UBS: Sought clarity on new vs. renewal patient mix. Vosseller said renewals have been slightly more than half, with MDI conversions about two-thirds of new starts, and expects a turnaround in new starts in 2026.
* Michael Kratky, Leerink Partners: Questioned pharmacy coverage conversion to actual payment. Vosseller explained contracts are in place and access is expanding, with 2025 focused on operational readiness for broader pharmacy scale in 2026.
* William Plovanic, Canaccord Genuity: Asked about Type 2 patient strategy. Sheridan said full commercial launch began in Q3, with positive feedback and further pharmacy and tubeless access expected to improve performance.

SENTIMENT ANALYSIS

* Analysts acknowledged the strong quarter but repeatedly pressed for more color on future growth catalysts, price uplift, and new patient trends, reflecting a slightly positive but cautious tone.
* Management maintained a confident and upbeat tone in prepared remarks, emphasizing transformation, innovation, and execution, and continued this confidence in the Q&A, frequently referencing positive trends and future opportunities.
* Compared to the previous quarter, management’s tone has shifted from cautious optimism to stronger confidence, particularly around pricing, pharmacy access, and product innovation, while analysts remain engaged but continue to probe on growth levers and competitive risks.

QUARTER-OVER-QUARTER COMPARISON

* Guidance remains consistent with the previous quarter, reaffirming the $1 billion sales milestone and gross margin targets.
* Strategic focus has shifted from piloting to fully promoting Type 2 diabetes initiatives and accelerating pharmacy channel expansion, compared to Q2’s pilot and early access phases.
* The previous quarter emphasized commercial transformation and the impact of a new competitor, while the current quarter highlights tangible results from those efforts and outlines concrete steps for 2026.
* Key metrics such as revenue, gross margin, and international sales show sequential improvement, with management’s confidence and tone notably more assertive about sustained growth and profitability.

RISKS AND CONCERNS

* Management acknowledged the risk of long-term pricing pressure in the pharmacy channel but indicated they are "preparing for that possibility" while capitalizing on current premium pricing.
* Vosseller noted headwinds from distributor inventory destocking and inventory buybacks as the company transitions to direct international operations, expecting a stronger impact in Q4.
* Analysts questioned the sustainability of pricing uplift, competitive rebating in the pharmacy channel, and the mix of new versus renewal patient starts, indicating ongoing concern about market dynamics and competition.

FINAL TAKEAWAY

Tandem Diabetes Care’s management reiterated confidence in reaching $1 billion in 2025 worldwide sales, supported by record Q3 results, robust pricing improvements, and expanding pharmacy channel access. With new product launches, international direct sales, and a shift to full commercial efforts for Type 2 diabetes, the company positions itself for gross margin expansion and renewed pump growth in 2026. Management’s focus on operational excellence, innovation, and commercial transformation underpins their outlook for sustainable leadership and future growth.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/tndm/earnings/transcripts]

MORE ON TANDEM DIABETES CARE

* Tandem Diabetes Care, Inc. (TNDM) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4839921-tandem-diabetes-care-inc-tndm-q3-2025-earnings-call-transcript]
* Tandem Diabetes Care, Inc. (TNDM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4821549-tandem-diabetes-care-inc-tndm-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* Tandem Diabetes Care: An Earnings Miss Confirms The Bear Case - Downgrade To Sell [https://seekingalpha.com/article/4811895-tandem-diabetes-care-earnings-miss-confirms-bear-case-downgrade-sell]
* Tandem Diabetes Care soars after double Q3 beats [https://seekingalpha.com/news/4518082-tandem-diabetes-care-soars-after-double-q3-beats]
* Tandem Diabetes Care GAAP EPS of -$0.31 beats by $0.05, revenue of $249.25M beats by $13.48M [https://seekingalpha.com/news/4517898-tandem-diabetes-care-gaap-eps-of-0_31-beats-by-0_05-revenue-of-249_25m-beats-by-13_48m]